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CHAPTER I GENERAL INTRODUCTION 
Dissertation Organization 
This dissertation contains three research papers preceded by a general 
introduction, and followed by a general discussion, a summary and a list of 
references cited in the general introduction and discussion. The general 
introduction includes research objectives and background information including 
literature review. Chapter II represents a paper that has been published in the 
Journal of Pharmacology and Experimental Therapeutics, and Chapters III and IV 
correspond to manuscripts to be submitted for publication in the Life Science and 
Journal of Pharmacology and Experimental Therapeutics, respectively. 
This dissertation contains most of the experimental results obtained by the 
author during the course of his graduate study under the supervision of his major 
professor, Dr. Walter H. Hsu. 
Research Objective 
Insulin is an important hormone in the regulation of carbohydrate 
metabolism. The pancreatic beta-cells, which secrete insulin, help the body convert 
ingested food into energy to be used by the organism. Insulin increases the storage 
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of glucose, fatty acid and amino acids by way of anabolic pathways. The 
physiological role of insulin is well known. However, the regulation of insulin 
secretion is not fully understood. Insulin deficiency in humans and animals, which 
is called diabetes, is a common and serious pathologic condition. Insulin 
deficiency commonly causes keto-acidosis and coma, but other complications 
associated with prolong hyperglycemia may also develop in long-standing diabetes. 
One of the factors which causes a deficiency of insulin secretion is a genetic 
modification during fetal development resulting in a loss of beta-cell generative 
capacity (Swenne, 1992). However, the intracellular regulation of insulin secretion 
and in the pancreatic beta-cells is still not well characterized (Ashcraft, 1994). 
Therefore, it is clinically and scientifically important to investigate the intracellular 
mechanisms of insulin secretion. 
A number of studies have shown that changes in the intracellular free Ca-"^ 
concentration, [Ca^"^];, play a central role in the regulation of insulin secretion in 
pancreatic beta-cells (Ashcraft, 1994). Insulin secretion is triggered by a rise of 
[Ca""^]; that results from the opening of Ca'"^ channels on the beta-cell plasma 
membrane and/or release of Ca^"^ from intracellular Ca^'" stores. However, 
activation of the effectors in the downstream of signal transduction such as 
phospholipases and protein kinases may regulate the changes in [Ca*"^]! and the 
secretion process. 
Therefore, the purpose of this research is to characterize the events 
3 
following signal transduction in the pancreatic beta-cells by using arginine 
vasopressin as a stimulator. To study vasopressin receptor-mediated signal 
transduction, we applied specific inhibitors of downstream effectors to pinpoint the 
role of each effector in insulin secretion. In addition, the interaction of effectors 
and second messegers were investigated. 
Background and Literature Review 
This section provides background information for the studies presented in 
this dissertation : (1) AVP-induced muUiple signal transduction pathways in 
pancreatic beta-cells; (2) Involvement of phospholipases in AVP-induced actions; 
(3) Involvement of protein kinase C in AVP-elicited action in pancreatic beta-cells. 
The organization of pancreatic islets 
The islets of Langerhans are ovoid, approximately 76 x 175 |im collections 
of cells scattered throughout the pancreas. The distribution of islets is more 
plentiful in the tail than in the body or head of the pancreas. They make up 1-2% 
of the weight of the pancreas. In humans, there are 1-2 million islets in each 
pancreas. Each islet has a copious blood supply; and the blood from the islets, like 
that from the gastrointestinal tract drains into the hepatic portal vein. The 
endocrine pancreatic cells are distributed within the islet along fenestrated 
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capillaries. 
The cells of the islet have been divided into several types based on their 
different staining properties and morphology. There are at least 4 distinct cell 
types: A, B, D, and F cells. The A cells secrete glucagon, the B cells (also called 
beta-cells) secrete insulin, the D cells secrete somatostatin, and the F cells secrete 
pancreatic polypeptide. The B cells, located in the center of the islets are the most 
common and make up 60-70% of the cells in the islet. The A cells make up 20% 
of the total and the D and F cells are less common. The A, D, and F cells 
surround the centrally located B cells. The organization of islet cells depends on 
cell adhesion molecules, which exist on the surface of endocrine cells. They share 
specific connections with each other and create a complex and heterogeneous 
micro-organ. 
Structure and biosynthesis of insulin 
Insulin is a polypeptide containing two chains of amino acids linked by 
disulfide bridges. There are minor differences (2 to 4 % of residues) in the amino 
acid composition of molecule from species to species. The differences are 
generally not sufficient to affect the biologic activity of a particular insulin in 
heterologous species but are sufficient to make the heterogenous insulin antigenic. 
Insulin is synthesized in the endoplasmic reticulum (ER) of beta-cells. The 
initial polypeptide, preproinsulin, encoded by insulin mRNA translocates across the 
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membrane of rough ER. During translocation, the signal sequence is cleaved by a 
signal peptidase which transforms preproinsulin to proinsulin, the precursor of 
insulin. The proinsulin molecule begins to fold and undergoes a rapid formation of 
disulfide bonds to gain its native structure. Proinsulin is then transported to the cis 
region of the Golgi apparatus for further processing and packing (Fig. 1). 
During the intracellular transport of proinsulin from ER to secretory 
granules, the 31-residue connecting peptide fragment (C-peptide) is cleaved to 
produce insulin. Both C-peptide and insulin are stored in the secretory granules. 
The secretory granules move to the plasma membrane by a process involving 
microtubules, their membranes ftise with the plasma membrane of the cell, 
expelling insulin to the exterior by exocytosis. 
Regulation of insulin secretion 
Insulin secretion is regulated by a complex of many signals, the most important 
of which is the concentration of glucose bathing the beta-cell. In addition, a 
number of neurotransmitters and islet peptides can also exert paracrine effects on 
insulin secretion (Gerich et al., 1976; Prentki and Matschinsky, 1987). 
Glucose-induced insulin secretion is mediated by an increase in the intracellular 
ATP concentration. ATP causes closure of ATP-sensitive potassium channels 
located in the plasma membrane which depolarizes the membrane. Membrane 
depolarization induces the opening of voltage-dependent calcium channels and 
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Fig. 1. The biosynthesis of insulin (Hazelwood, 1989). 
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beta-cell electric activity. The Ca^"" influx increases [Ca^""]) and elicits exocytosis of 
insulin-containin secretory granules (Fig. 2). 
Extracellular regulatory molecules of insulin secretion, such as hormones, 
neurotransmitters, and growth factors, interact with cells by binding to specific cell 
surface receptors. As a result of this interaction, the receptor may be activated 
thereby leading to the generation of second messenger molecules. 
Several receptor families associated with different mechanisms have been 
characterized and classified. Most of the receptors are coupled to regulatory 
guanine nucleotide-binding proteins (G proteins). G proteins transmit the signal to 
effectors (such as enzymes or ion channels) which transduce the binding of a 
ligand into an intracellular signal, such as changes in the concentration of diffusible 
second messengers or the gating of ion currents (Offeermanns and Schultz, 1994). 
p-Adrenergic receptors and glucagon-like polypeptide (GLP) receptors activate a G 
protein, Gj, which activates the downstream effector adenylyl cyclase (AC) and 
thus generates cAMP. This second messenger may activate protein kinase A 
(PKA) or regulate Ca^^ channels directly (Ashcraft, 1994). Somatostatin receptors 
and ttj-adrenergic receptors activate a G protein, Gj, which inhibits the downstream 
effector AC and inhibits the generation of cAMP. Receptors for vasporessin, 
bombesin, cholecystokinin (CCK) and bradykinin activate a G protein, Gq, which 
activates the downstream effector phospholipase C (PLC) and thus generates IP3 
and diacylglycerol (DAG). These ligand receptor interactions selectively 
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filter the incoming signals from extracellular stimuli. Extracellular stimuli 
converted by the plasma membrane network are in a complex of integration 
processing and allow the cells to generate an adequate response. 
Regulation of insulin secretion bv vasopressin 
Chemistry and synthesis of AVP 
Arginine vasopressin (AVP) is a nonapeptide, with a molecular weight of 1084 
Da, and is a strongly basic molecule (Schally, 1972). Synthesis of the AVP 
precursor occurs principally in the supraoptic and paraventricular nuclei of the 
hypothalamus. As the precursor complex migrates along the neuronal axons at a 
rate of about 2 mm/h, it undergoes specific cleavage, and the products that include 
AVP are stored as neurosecretory granules in the posterior pituitary gland (Russel 
et al., 1990). Release of AVP from the neural lobe is associated with an increase 
in the rate of phasic firing of electrical impulses (Dutton and Dyball, 1979). 
Expression of the AVP gene has been observed in extrahypothalamic 
tissues, such as the adrenal gland, gonads, cerebellum and probably the pituicytes 
of the posterior pituitary gland (Richter et al., 1991). 
Function of A VP 
AVP, the antidiuretic hormone, plays a major role in the regulation of body 
fluid volume and osmolality. It also contributes to the maintenance of blood 
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pressure and other physiological functions. For example, AVP increases 
glycogenolysis, corticotropin release, water reabsorption from the collecting duct, 
platelet aggregation, release of coagulation factors, firing rate of certain neurons 
(Thibonnier, 1992), proliferation of the pituitary gland and vascular smooth muscle 
cells (McNicol et al., 1990; Sperti and Colucci, 1991) and increases secretion of 
the glucagon and insulin (Dunning et al., 1984). All of these actions are mediated 
through activation of specific receptors present on the surface of the target cells. 
A VP receptors 
There are two types of vasopressin receptors : V, and Vj (Michell, et al., 
1979). Activation of vascular and hepatic AVP receptors, classified as V, receptors, 
leads to an increase in IP3 formation and a rise of [Ca^^]j (Thibonnier, 1992). 
Based on the fact that the AVP receptors in the anterior pituitary cells have a 
slightly different pharmacological profile in terms of their binding characteristics of 
AVP analogues, the term V,b was proposed to distinguish them from the classical 
vascular V,j, receptors (Schwartz et al., 1991). In contrast, renal AVP receptors, 
classified as V2 receptors, are involved in free water reabsorption via activation of 
adenylyl cyclase (Thiboimier, 1992). 
The presence of immunoreactive AVP, in nanomolar concentrations in the 
mammalian pancreas (2-11 ng/g wet wt) (Amico et al., 1988), suggests a pancreatic 
site of production since peripheral plasma levels are considerably lower (1-2 pg/ml) 
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in normal man (Scrier et al., 1979). In addition, administration of AVP has been 
shown to increase plasma insulin concentrations in man (Karp et al., 1968). A 
number of animal studies concerning the effects of AVP on insulin secretion 
indicate that AVP is capable of influencing islet cell function (Altszuler and 
Hampshire, 1981, Stock and Uvnas-Moberg, 1987, Dunning et al., 1984). AVP 
stimulates insulin secretion firom isolated mouse pancreatic islets (Gao et al., 1990), 
cloned insulin-secreting cell lines RINmSF cells (Monaco et al., 1988) and hamster 
insulin-secreting tumor (HIT) cells (Richardson et al., 1990). We have recently 
found that AVP-induced insulin secretion is mediated by V,,, receptors in rat islets 
and RINmSF cells (Lee et al., 1995). 
Signal transduction pathway of V, receptors 
AVP has been widely studied in several different cell models, such as smooth 
muscle, endocrine cells, and endothelium (Spatz et al., 1994). The signal 
transduction pathway of AVP receptors in insulin secretion has been investigated 
by using cell lines (RINmSF and HIT) and pancreatic islets. AVP binds V, 
receptors which are coupled to the P,-subtype of phospholipase C (PLC) by certain 
GTP-binding (G) proteins of the G, family (Lee and Severson, 1994). G proteins 
are heterotrimers consisting of a, P and y subunits. The a subunit binds guanine 
nucleotide and appears to play the major role in activating the effector enzyme or 
ion channel. A role for the P and y subimits in activating or modifying the 
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activation of some effectors has been foimd in a limited number of cases. When 
stimulated by AVP, this receptor couples to PLC and accelerates the rate of 
phosphatidylinositide 4,5-bisphosphate (PIP2) hydrolysis. This leads to the 
formation of inositol 1,4,5-triphosphate (IP3) and 1,2-diacylglycerol (DAG) 
molecules that act as second messengers by releasing Ca^^ from intracellular stores 
and by activating protein kinase C (PKC), respectively (Nishizuka, 1992 and 
Thibonnier, 1992). In addition, AVP activates other effectors, such as PLA, and 
PLD (Fig.3). The AVP-induced Ca^" influx through opening of Cs?* channels is 
mediated by PLAj in the smooth muscle cell line AJT^ (Thibonnier et al., 1992). In 
the Swiss 3T3 fibroblasts (Briscoe and Wakelam, 1995) and L6 myoblasts 
(Thompson et al., 1994), AVP stimulates PLD activity. The AVP-induced PLC-
mediated signal pathway is well characterized in several different insulin secreting 
cell models (Gao et al., 1994, Li et al., 1990, and Richardson et al., 1990). 
However, in the pancreatic beta-cells, the other signal transduction pathways 
induced by AVP are not well characterized. This prompted us to study the role of 
PLA2 and PLD in AVP-induced [Ca^"^], increase in the beta-cells. 
Involvement of ohospholipases in AVP's action 
Phospholipase C 
PLC is a family of enzymes that hydrolyze phospholipid at the 3-position 
phosphodiester bond of the glycerol backbone. When PIPj is the substrate, PLC 
;tccristi 
Phcsphellcasa C Phcsphciipasa 0 Phcsphclipasa Aj 
S^^ Iv y 
I Potentiaticn 
Calluiar Responses 
Agonist Time 
Fig. 3. Schematic representation of the agonist-induced membrane phospholipid 
degradation (A). Time course of generation of various signalling molecules (B). 
(Nishizuka, 1992) 
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action leads to the formation of IP3 and DAG. 
PPI-specific PLC (PPI-PLC) is a subfamily of PLC that acts specifically on 
inositol-containing lipids and does not hydrolyze other phospholipids, such as 
phosphatidylcholine (PC) (Lee and Severson, 1994). PPI-PLC can be divided into 
three types (p, y and 6), which are distinct proteins that exhibit only a small 
amount of sequence identity. In cells, p and y isoenzymes appear to be the ones 
that are involved in the receptor-activated PIPj hydrolysis, but the mechanisms of 
their activation are different. PLC-p is activated by Gq-mediated signal 
transduction, and PLC-y is activated by tyrosine kinase receptor activation (Asaoka 
et al., 1992). A difference in the primary amino acid sequences between p and y 
isoenzymes, which are related to their mechanisms of activation, is that PPI-PLC-y 
contains src homology (SH2 and SH3) domains, whereas PPI-PLC-P does not. 
SH2 and SH3 domains mediate the binding to other proteins that contain 
phosphorylated tyrosine residues, for example, growth factor receptors (Rhee and 
Choi, 1992). 
In insulin-secreting cells, AVP induces insulin secretion by promoting the 
production of IP3 which increases [Ca^""]; (Li et al., 1992). In addition, AVP may 
stimulate insulin secretion by closing ATP-sensitive K" channels, thereby 
promoting membrane depolarization (Martin et al., 1989). This in turn increases 
Ca^^ influx by opening voltage-dependent Ca^"" channels (VDCC) (Thorn et al., 
1991). 
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Phospholipase A 2 
PLA2 enzymes catalyze the hydrolysis of the ester linkage in the membrane 
glycerophospholipids at the sn-2 position of the glycerol moiety. These enzymes 
can generally be divided into two major groups, the extracellular or low molecular 
mass (14-18 kDa) forms, secretory PLAj (sPLAj), and the intracellular or high 
molecular mass (31-110 kDa) forms, termed cytosolic PLAj (cPLAj) (Glaser et al., 
1993). Table I shows the major differences between two groups of these enzymes. 
The sPLAj enzymes are the most highly characterized group of PLAj enzymes due 
to their universal nature and high concentration in venoms of snakes and pancreatic 
juices (Verheij et al., 1981). The characteristics of cPLAj are considered important 
for intracellular regulated enzymes responsible for the release of arachidonic acid 
for eicosanoid biosynthesis (Glaser et al., 1993). The cPLAj enzymes display a 
preference for arachidonic acid-contained phospholipid and have an almost absolute 
requirement for unsaturated fatty acids in the sn-2 position of glycerophospholipids. 
In the pancreatic beta-cells, several studies have sought to identify positions 
in the stimulus-secretion signal pathway of insulin release affected by the action of 
PLA2 (Fujimoto and Metz, 1987; Zawalich and Zawaich, 1985; Yamamoto et al., 
1983). It has been demonstrated that three distinct points in the signal pathway of 
insulin secretion appear to be affected by PLAj; one is influx, the second is 
Ca^"" release, and the third which is independent of a rise in [Ca^""], (Eddlestone, 
1995). There are three types of PLAj enzymes expressed in pancreatic beta-cells; 
16 
Table I. Comparison of sPLA, and cPLAj (Glaser, 1995) 
sPLA, cPLAi 
Form Secretory Intracellular 
Molecular weight — 14 kDa -100 kDa (SDS-PAGE) 
-82 kDa (cDNA) 
Ca*- rcquirenieni Absolute Only for translocation 
Regulation Transcriptional (IL-1, IL-6- Transcriptional (lL-1 induced) 
induced) Phosphorylation (MAPK) 
Ca*^ levels (enzyme activity) 
Catalytic residue His Ser' 
Substrate specificity 
Head group None None 
sn-2 fatty acid None Arachidonyl selective 
Other enzymatic None Lysophospholipase 
activities Transacyiase (?)'' 
•' The role of an active site Ser was proposed by Trimble el al. (1993) based on NMR studies 
with cPLA. and a trifluoromethyl ketone inhibitor. 
''The transacyiase activit)' of cPLA, was described by Reynolds et al. (1993) and used specific 
assay conditions to observe this activiry. It is not known whether this activity exists under 
normal physiological conditions. 
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two of them are membrane-associated, and one is cytoplasmic. In insulin-secreting 
cells, PLAj activity is increased in the presence of glucose (20 mM) (Ramanadham 
et al., 1993). Therefore, it has been proposed that PLAj may play a role in 
nutrient-induced insulin secretion (Konrad et al., 1992; Ramanadham et al., 1993). 
Also the endogenous polypeptide, gastric inhibitory polypeptide, inhibits the 
activity of PLAj (Lardinois et al., 1990). This suggests that PLAj is involved in 
the regulation of insulin secretion in the pancreatic beta-cell. 
The PLAj enzymes have been shown to be involved in AVP-induced signal 
transduction (Spatz et al., 1994; Loxley, et al., 1993). However, the role of PLA, 
in AVP-induced insulin secretion from beta cells remains poorly defined. 
Phospholipase D 
PLD was described for the first time in 1947 in plants (Hanahan and 
Chalikoff, 1947) and was later found in mammals (Saito and Kanfer, 1973). PLD 
hydrolyses phosphatidylcholine (PC) and cleaves the phosphodiester bond distal to 
the glycerol backbone resulting in the formation of phosphatidic acid (PA) and 
choline. Its activation by various agonists has been described in many tissues and 
cell models (Boarder, 1994). The regulation of PLD activity seems to occur 
through several different mechanisms depending on the cell type and agonist. 
Various factors are involved in its activation such as G proteins, hydrolysis of PIPj, 
activation of PKC, stimulation of calmodulin/myosin light chain kinase and 
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phosphorylation on tyrosine residues (Boarder, 1994). 
There is clear evidence that a receptor-dependent PLD is present in a 
number of tissues. Agonists, such as bradykinin (Horwitz and Ricanati, 1992), 
bombesin (Briscoe et al., 1994) and prostaglandin Fja (Sugiyama et al., 1994), 
stimulate the hydrolysis of PC via PLC and PLD. This leads to an increase in the 
production of DAG and phosphocholine in one pathway and PA and choline in the 
other (Rydzewska et al., 1993). PA is hydrolyzed by phosphatidic acid 
phosphohydrolase (PPH) to produce DAG. This signal transduction pathway 
provides an alternative source of DAG. The initial product of PLD activation is 
PA which has been suggested to be a second messenger (Thompson et al., 1991). 
PLD activation in the stimulation of insulin release was found in pancreatic islet 
cells (Dunlop and Metz, 1989; Metz and Dunlop, 1990). However, the role of 
PLD in agonist-induced insulin secretion is not well understood. 
AVP-induced TCa^^l increase 
In most of cells, several polypeptide receptors such as AVP, bradykinin, 
bombesin, and oxytocin mediate a biphasic increase in [Ca^"]; with a transient peak 
followed by a sustained phase. The initial phase is due to the Ca""^ release from 
intracellular stores, the sustained phase is mediated by Ca^"^ influx which involves 
both the voltage-dependent Ca^^ channels and voltage-independent Ca^"^ channels 
(Chen et al., 1994). Activation of VDCCs and voltage-independent Ca^^ channels 
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by PLC-coupIed receptors has been reported (ZhuGe et al., 1995); however, the 
mechanisms underlying the receptor-activated sustained influx are not yet 
clear (Clapham, 1995). 
In recent years, an attractive theory has been developed to account for the 
PLC-mediated influx. This is called capacitative Ca*"^ entry mechanism 
(Putney, 1990). This theory indicates that the depletion of intracellular Ca*^ store 
evokes Ca^"" influx through opening of Ca*"" channels. Among the putative Ca"^ 
channels is a v^^ell-established ion channel that elicits Ca^" release-activated Ca*"^ 
current (ICRAC)- This channel has been characterized in several cell types such as 
mast cells (Hoth and Penner, 1992), pancreatic acinar cells (Bahnson et al., 1993), 
human T cells (Lewis and Cahalan, 1989), and A431 cells (Luckhoff and Clapham, 
1994). ICRAC has an extremely low conductance of most ion channels. The net 
current passing the channels in the whole cell is ~ 5 pA. ICRAC is highly Ca""^-
selective and is inactivated by high intracellular levels (Fasolato et al., 1994). 
There are other types of Ca^^ currents triggered by Ca"" store depletion such as 
depletion of internal Ca^* stores-activated Ca^^ current (I^c). IPa-activated Ca^"^ 
current (Ica.iP3). IP4-activated Ca^* current (Ica,iP4)» ATP-activated Ca^"" current 
(Ica.ATp)» Ca^^-activated Ca^"^ current (Ica.ca)' ^nd voltage-dependent Ca^* currents 
(Clapham, 1995). Except for the voltage-dependent Ca^^ currents, none of these 
putative ion channels have been purified or cloned. 
The second major question in the capacitative theory is: how does the depleted 
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intracellular Ca^"^ stores open the plasma membrane Ca^" channels? One of the 
popular hypotheses is that depletion of intracellular stores releases a novel 
small messenger, influx factor (CIF) that activates Ca^^ channels 
(Randriamampita and Tsien, 1993; Clapham, 1995). CIF is the most interesting 
second messenger candidate to initiate ICRAC- was initially isolated from Jurkate 
T cells after the depletion of Ca*"^ stores by phytohemagglutinin treatment 
(Randriamampita and Tsien, 1993). CIF caused Ca^^ influx when applied to 
macrophages, astrocytoma cells, and fibroblasts. It has been partially characterized 
as a < 500 Da phosphorylated pH-stable anion substance. CIF is probably released 
or generated from the ER or adjacent regions after IPj-induced Ca^"" release from 
stores (Clapham, 1994). 
Currently, key issues to be settled in this field include: 1) characterization of 
Ca^^ entry pathways that are mediated by store depletion, and 2) characterization of 
direct messengers that mediate the store-depletion signal. 
The role of PKC on AVP-induced insulin secretion and changes in intracellular 
Oil 
One of the downstream effectors of both PLC and PLD pathways is the 
generation of DAG which activates PKC. DAG, in combination with 
phosphatidylserine (PS) activates PKC. PKC, in turn, phosphorylates a number of 
regulatory proteins producing additional effects such as stimulation of secretion and 
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transcription (Nishizuka, 1988). 
PKC is a serine and threonine kinase; it phosphorylates serine and threonine 
residues in protein substrates but does not phosphorylate tyrosine residues. PKC 
activation is thought to require translocation from cytosol to plasma membranes. 
Although it was initially thought that PKC was activated only when it becomes 
associated with the plasma membrane, there is evidence that PKC can also be 
associated with and be activated within the membrane of the nucleus (Nishizuka, 
1992). 
PKC belongs to a family of at least ten isoenzymes. Additional PKC 
isoenzymes are currently being identified by reverse transcription of total RNA 
(Chang et al., 1993). PKC isoenzymes have been grouped into three classes 
(Dekker and Parker, 1994). The conventional PKCs (cPKC) PKC- a, -pi, -pll, 
and -T are Ca^"^- and phospholipase-dependent enzymes, the novel PKCs (nPKC) 
PKC -5, -e, -T) and -0 are Ca^'^-independent but phospholipid-dependent. The 
atypical PKCs (aPKC) PKC-^ and -A, are not activated by DAG or phorbol esters 
(Table 11). The Ca^'^-dependent PKC may require both the generation of DAG and 
elevation of [Ca^^]j of receptor mediated activation of PLC in vivo, whereas the 
Ca^^'-independent isoenzymes may be activated by phospholipid alone. It has been 
suggested that activation of different PKC isoenzymes in vivo may lead to distinct 
cellular responses (Dekker and Parker, 1994). This could occur if different 
isoenzymes phosphorylate distinct proteins. It is also possible that activation of 
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Table II Subspecies of protein kinase C (Dimitrijevic et al., 1995) 
laoform Lipid AcdvaCars 
Ca-••-dependent PKC 
Classical PKC a* PS, DAG (PhE). FA, LPC 
PS, DAG (PhE). FA, LPC 
7 PS. DAG (PhE), FA. LPC 
Ca-"-independent PKC 
New PKC S PS, DAG (PhE). FA 
€* PS, DAG (PhE). FA 
•n ND 
8 ND 
Atypical PKC ?• PS. FA 
1 ND 
PS, phosphatidyiserine; PKC, protein kinase. C; DAG, diacylgiyc-
erol; PhE, phorbol ester; FA, fatty acid; LPC, lysophdsphatidylcholine. 
ND, not determined. "Present in vascular smooth muscle. 
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different isoenzymes may occur because they are present in different cellular 
compartments. Differential regulation of PKC isoenzyme has been shown to occur 
during stimulation of a single cell type by a single agonist (Dimitrijevic et al., 
1995). This suggested that PKC may play multiple roles in the regulation of 
cellular processes. 
All PKC isoenzymes consist of two fimctional domains, a carboxyl-terminal 
catalytic domain which is involved in substrate phosphorylation and an amino-
terminal regulatory domain which is involved in the binding of regulatory cofactors 
and activators (Nishizuka, 1988). These fimctional domains contain four conserved 
regions (C1-C4) and five variable regions (V1-V5). A phorbol ester binds to the 
CI region of the PKC enzyme and acts by mimicking the action of DAG 
(Nakamura et al., 1989). The binding of intracellular Ca^"" to the C2 region of 
cPKC causes translocation of these enzymes to the plasma membrane where they 
are activated following binding to DAG and PS. 
PKC is involved as a modulator of multiple steps regulating the pancreatic 
beta-cell stimulated-secretion coupling. The stimulation of PKC by DAG may 
regulate the functional response in the cell and may play a negative feedback 
control role in signal transduction (Nishizuka, 1992). In the normal mouse 
pancreatic beta-cells, PKC plays a negative feedback control role in the responses 
to acetylcholine and vasopressin to inactivate PLC (Gao et al., 1994). On the other 
hand, activation of PKC with phorbol esters increases insulin release in normal 
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pancreatic cells and HIT cells (Arkhammer et al., 1994). However, the role of 
PKC in beta-cells is controversial because the tools used in these studies are not 
specific and, thus the resuhs are difficult to interpret. For example, phorbol esters 
that are used as to activate of PKC may exert additional effects that are not related 
to PKC activation (Wilkinson and Hallam, 1994). Therefore, phorbol esters 
stimulate insulin secretion in some studies (Manaco et al., 1988). In addition, the 
PKC inhibitor (staurosporine) applied to confirm the specificity of PKC's effects, 
also has additional effects which are not related to PKC activation (Wilkinson, and 
Hallam, 1994). These include the inhibition of protein kinase A, calmodulin and 
tyrosine kinase (Davis et al., 1989). Currently there are several specific PKC 
inhibitors (e.g., Ro 31-8220) available to study the mechanism of PKC in 
regulation of insulin secretion. Ro 31-8220 is a derivative of staurosporine which 
is superior to staurosporine (Davis et al., 1989) and is a potent and selective 
inhibitor of protein kinase C. As mentioned earlier, PKC may be a negative 
regulator of cell responses. Ca^* is an important intracellular signal which 
regulates the cell responses and it has been reported that PKC activation regulates 
Ca^"^ channels (Mullen, 1995; Sena et al., 1995). Therefore, it is important to 
characterize the role of PKC in the regulation of intracellular Ca^" by using specific 
PKC inhibitors. In a preliminary study, we also found that inhibition of PKC by 
Ro 31-8220 enhanced AVP-induced Ca^^ influx. These results suggested that PKC 
may inhibit the AVP-induced intracellular Ca^"^ change in beta-cells. Ca^" entry 
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through VDCC is a major pathway for raising [Ca^""]; in most living cells including 
beta-cells (Ashcroft et al., 1990 and Smith et al., 1993). It would be important to 
characterize the types of Ca?* channels that are involved in the inhibition of insulin 
secretion by PKC. 
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CHAPTER n ARGININE VASOPRESSIN-STIMULATED INSULIN 
SECRETION AND ELEVATION OF INTRACELLULAR Ca^^ 
CONCENTRATION IN RINmSF CELLS: INFLUENCES OF A 
PHOSPHOLIPASE C INHIBITOR U-73122 AND PHOSPHOLIPASE A^ 
INHIBITOR N-(P-AMYLCINNAMOYL)ANTHRANILIC ACID 
A paper published in the Journal of Pharmacology and Experimental Therapeutics' 
Ter-Hsin Chen, Bumsup Lee and Walter H. Hsu" 
ABSTRACT 
The present study was undertaken to investigate the mechanism by which 
arginine vasopressin (AVP) increases insulin secretion in rat insulinoma (RINmSF) 
cells by using a specific phospholipase C (PLC) inhibitor, U-73122, and a 
phospholipase A2 (PLAj) inhibitor, N-(p-amylcinnamoyl)anthranilic acid (ACA). 
AVP (0.1-100 niv!) increased insulin secretion and cytosolic free Ca^^ concentration 
'Reprinted with permission from J. Pharmacol. Exp. Ther. 1994, 207, 400-404. 
Copyright @ 1994 J. Pharmacol. Exp. Ther. 
^ Author for correspondence. 
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([Ca^^^Ji) dose-dependently. Moreover, U-73122 (2-8 |iM) inhibited the A VP-
induced increases in the intracellular concentration of inositol 1,3,4-trisphosphate 
(IP3) and [Ca^^Jj dose-dependently. At 8 j^M U-73122 abolished the AVP's effect 
on IP3 and [Ca"^]j, but it only reduced the AVP-induced increase in insulin 
secretion by 35%. In contrast, 8 |LIM U-73122 did not reduce the ionomycin (a Ca"^ 
ionophore, 100 nM)-induced increase in [Ca^^'ji. The discrepancy between the 
results of [Ca*"^]; and insulin secretion may be due to the multiple signal 
transduction pathways associated with the activation of AVP receptors, specifically 
the Ca^^-independent pathway. The phospholipase Aj inhibitor ACA (100 jiM) did 
not antagonize the AVP (10 nM)-induced increase in insulin release. These results 
suggested: 1) U-73122 blocks PLC activhies but fails to block other signal 
transduction pathways that trigger insulin secretion in these cells, and 2) AVP 
increases insulin release from RINmSF cells through both the PLC mediated Ca""^-
dependent and Ca^^'-independent pathways. 
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INTRODUCTION 
Arginine vasopressin (AVP) is a neurohypophyseal nonapeptide hormone 
with antidiuretic effects on the kidney and pressor action on the vascular smooth 
muscle. AVP binds to V,-receptors and activates PLC, which in turn hydrolyzes 
phosphatidylinositol 4,5-bisphosphate to diacyiglycerol (DAG) and IP3 (Nishizuka, 
1992; Thibonnier, 1992). DAG activates protein kinase C, whereas IP3 increases 
the release of calcium from the endoplasmic reticulum to elevate [Ca"^];. 
The aminosteroid U-73122 (l-[6-[[17p-3-methoxyestra-l,3,5(10)-trien-17-
yl]amino]hexyl]-lH-pyrrole-2,5-dione) inhibits a variety of PLC mediated events, 
in human neutrophils and platelets (Bleasdale et al., 1990; Smith et al., 1990; 
Vickers, 1993), human neuroblastoma cells (Thompson et al., 1991), human 
erythroleukemia cells (Wu et al., 1992), GH3 rat pituitary cells (Smallridge et al., 
1992; Hawes et al., 1992), rat hepatocytes (Galan et al., 1992) and rat pancreatic 
acinar cells (Yule and Williams, 1992). 
In insulin-secreting cells, AVP induces insulin secretion by promoting the 
production of IP3 which increases [Ca-^]j (Li et al., 1992). In addition, AVP may 
stimulate insulin secretion by closing ATP-sensitive channels and thus 
promoting membrane depolarization (Martin et al., 1989), which in turn may 
increase Ca^"" influx directly by opening vohage-dependent Ca^" channels (Thorn et 
al., 1991). 
The AVP-induced increase in Ca^'^ influx is mediated by PLAj in the 
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smooth muscle cell line Ayfj (Thibonnier et al., 1991). Glucose activates PLA, 
thus increases the formation of arachidonic acid, which mobilizes Csr* from the 
endoplasmic reticulum and regulates voltage-dependent Ca*"^ channel in the 
pancreatic-beta cell (Konrad et al., 1992). ACA, a PLA, inhibitor, inhibits 
glucose-induced insulin secretion in rat pancreatic islets (Konrad et al., 1992). 
The present study was undertaken to determine the mechanisms by which 
AVP induces insulin secretion in pancreatic-beta cells by measuring [Ca-"^],, IP3 
production, and insulin secretion. Specifically, we studied the effects of this 
inhibitor on PLC-dependent processes in RINmSF cells and the involvement of 
PLA2 in the AVP action by using the PLAj inhibitor ACA. 
METHODS 
Cell culture. RINmSF cells were maintained in RPMI 1640 containing 10% fetal 
bovine serum and aerated with S% C02-9S% air at 37°C as previously described 
(Thomas et al., 1989). All experiments were performed with cells in passages 4S-
S4. 
Insulin secretion. RINmSF cells were plated into 24-well Costar plates at 2 x 10' 
cells/well and grown for S days. Growth medium was removed and the monolayer 
cells were washed with modified Krebs-Ringer bicarbonate buffer (KRB) 
containing (in mM): 136 NaCl, 4.8 KCl, 1.2 CaCls, 1.2 KH2PO4, 1.2 MgS04, S 
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NaHCOj, 10 HEPES, 4 glucose, and 0.1% bovine serum albumin, and pH 7.4. 
The cells were then preincubated for a 30-min basal period at 37°C, followed by a 
15-min incubation in KRB with the test agent. When needed, U-73122 or ACA 
was given 5 min before the administration of AVP. The supematants were 
collected for radioimmunoassay (RIA) of insulin (Hsu et al., 1990). To measure 
insulin secretion in suspended cells, 1.5 x 10® cells were suspended in a test tube 
(12 X 75 mm") with 1.5 ml of KRB, then incubated for 5 min with the test 
reagents under gentle shaking with an orbit shaker (50 rpm) at 24°C. When 
needed, U-73122 was given 100 s before the administration of AVP. The reaction 
was terminated by centrifugating the cells and collecting the supematants for RIA 
of insulin. 
Measurement of FCa'""!;. To measure [Ca-""]! in all suspensions, 30 x 10^ cells were 
loaded with 2 |aM of fura-2 acetoxymethylester (fura-2AM) in KRB for 30 min at 
37°C. The loaded cells were washed and kept at 24°C until use. The cells were 
resuspended in a concentration of lOVml and 1.5 ml of aliquot was used for [Ca""^], 
determination at 24°C. The 340/380 nm fluorescence ratios were monitored in a 
SLM-8000 fluorescence spectrophotometer (SLM, Urbana, IL). The [Ca^^]| was 
calibrated after the cell lysis as described previously (Hsu et al., 1990). When 
needed, U-73122 was given 100 s, and [ethylenebis (oxyethylenenitrilo) tetraacetic 
acid (EGTA) or nimodipine was given 30 s before the administration of AVP. 
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Measurement of IP,. IP3 was quantified by use of a competitive radioreceptor-
binding assay kit (Du Pont Co., Boston, MA). 1.5 x 10® cells in 1 ml of KRB 
were placed in polypropylene tubes and incubated in a shaking water bath at 37°C. 
Incubation with the test agent was terminated in 10 s by adding 20% (w/v) of ice-
cold trichloroacetic acid. When needed, U-73122 was given 100 s before the 
administration of AVP. 
Statistical Analyses. Results were analyzed by the Student's t test for paired and 
unpaired values. The significance level was set at P< 0.05. 
Materials. The following were used: nimodipine (Research Biochemicals 
International, Natick, MA), ionomycin (Sigma Chemical Co., St. louis, MO), fura-
2AM (Molecular Probes, Eugene, OR), U-73122 and ACA (Biomol Research 
Laboratory, Plymouth meeting, PA). 
RESULTS 
Effects of U-73122 and ACA on the AVP-induced increase in insulin secretion 
AVP (0.1-100 nM) caused a dose-dependent increase in insulin secretion 
(Fig. 1). AVP (10 nM) induced an increase of about 2.5 times over basal insulin 
secretion. However, 1 ^M of AVP caused significantly less insulin secretion than 
100 nM of AVP. U-73122 (1-8 ^iM) alone did not change basal insulin secretion. 
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but it inhibited the AVP (10 nM)-induced insulin secretion dose-dependently. At 
the highest concentration studied (8 |JM), U-73122 inhibited approximately 30-35% 
of AVP-induced insulin secretion in both the monolayer (Fig. 2a) and suspended 
cell preparations (Fig. 2b). A PLA, inhibitor ACA (100 |j,M) did not affect AVP 
(10 nM)-induced insulin secretion (ACA + AVP=138.4 ± 8.52 pg/min/well, n=4; 
AVP=144 ± 7.4 pg/min/well, n=4, p>.05). 
Effects of AVP on FCa^""]; 
When AVP (1 nM - 1 |a.M) was applied to suspended RINm5F cells loaded 
with fura-2, it caused a dose-dependent increase in [Ca^^]; (Fig. 3). The rise in 
[Ca^^^jj after AVP administration usually reached a maximum within 30-40 s (The 
first phase) and decreased to a sustained level for the following > 4 min (The 
second phase). The second phase of increase in [Ca^^ji was seen in all doses 
studied, but was diminished at 1 ^iM AVP (Fig. 4). In the presence of 2 mM 
EGTA, AVP only evoked a single [Ca"""]; transient which was smaller than AVP in 
the absence of EGTA (Fig. 5). Nimodipine (1 nM), an L-type channel 
blocker, reduced but did not abolish the AVP-elicited rise in [Ca^^]i particularly in 
the second phase (Fig. 6). 
Effects of U-73122 on the AVP-induced increase in rCa^'^lj 
U-73122 alone did not change [Ca^"^]; until 8 )iM was given, which 
increased [Ca^^], by 10%, and subsided within 100 s of administration. 
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Pretreatment with U73122 (1-8 |iM) for 100 s inhibited the AVP (10 nM)-induced 
increase in [Ca^^]; dose-dependently. U-73122 at 8 abolished the AVP-elicited 
increase in [Ca"'^]; including the peak and second phase (Fig. 7). lonomycin (100 
nM) elicited a biphasic increase in [Ca^""]; with the pattern similar to that induced 
by AVP (10 nM). U-73122 (8 ^M) failed to affect the ionomycin-induced increase 
in [Ca-^]i (Fig. 8). 
Inhibition by U-73122 of the AVP-induced production of IP, 
AVP (100 nM) increased IP3 production by >200% of the basal level. U-
73122 (2, 4, and 8 |4.M) inhibited the AVP-stimulated production of IP3 in RINmSF 
cells in a dose-dependent manner (Fig. 9). U-73122 (8 |iM) almost abolished the 
AVP-induced increase in IP3 production. 
DISCUSSION 
Ca""^ plays a central role in the stimulation of insulin secretion (Wollheim 
and Pozzan, 1984). For example, glucose raises [Ca^^]j by opening voltage-
dependent charmels through depolarization induced by closing ATP-sensitive 
channels (Findlay and Dunne, 1985; Lu et al., 1993). Also, some of the 
neurotransmitters and hormones induce insulin secretion by activating adenylyl 
cyclase or phospholipases to mobilize Ca^"^ into the cytosol (Li et al., 1992). The 
second phase of increase in [Ca^"^]; maybe due to a rise in Csc* influx because the 
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Ca"^ chelator EGTA blocked this increase in our studies. AVP opens Ca'" 
channels in excitable cells, particularly in the smooth muscle (Van Renterghem, 
1988). The Ca^"^ channels that are opened by AVP administration are not all L-
type channels, since nimodipine, an L-type channel blocker, only partially reduced 
the Ca^"^ influx elicited by AVP. Our results confirmed and extended those of 
others (Li et al., 1992) and showed that AVP elicited an increase in [Ca"*]) by 
promoting the release of intracellular Ca-" store and Ca"" influx through channels 
including L-type channels (Thorn et al., 1991). 
U-73122 is a specific PLC blocker which has been used as a 
pharmacological tool in many different cell preparations to block the formation of 
IP3 and DAG (Bleasdale, 1992). In the present study, we found that U-73122 
inhibited the A VP-induced increase in [Ca-^]i and IP3 dose-dependently. The 
highest dose of U-73122 studied (8 ^M) abolished the AVP-induced increase in 
[Ca-^^Ji and IP3. The effect of U-73122 was a specific one because it did not affect 
the ionomycin-induced increase in [Ca^^],. lonomycin raises [Ca'^^Jj in RINmSF 
cells predominantly by increasing Ca^"" release from the endoplasmic reticulum 
(Swope and Schonbrunn, 1988). 
AVP increases the release of Ca""^ from the endoplasmic reticulum and Ca""" 
influx, and the high [Ca-""]; promotes insulin release (Li et al., 1992). In the 
present study, U-73122 inhibited the AVP-induced increase in [Ca^""]) much more 
than it affected insulin secretion. For example, U-73122 at 8 |iM abolished the 
increase in [Ca^"]) induced by AVP, but only reduced the A VP-elicited increase in 
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insulin secretion by < 35% in monolayer cells. We also used suspended cells, in 
the same condition as the [Ca^"]} measurement, to investigate the effect of U73122 
on AVP-elicited increase in insulin secretion. The results were similar to those by 
the use of monolayer cells. AVP causes multiple signal transduction mediated by 
V, receptor in the smooth muscle cell line (Thibonnier et al., 1991). In the 
present study, the discrepant results between [Ca^"^]; and insulin secretion may be 
due to multiple signal transduction pathways involved in the AVP-induced increase 
in insulin secretion, particularly the Ca^^-independent pathways. It is generally 
accepted that AV? activates V,-receptors that are coupled to a G-protein-Gq. Gq, in 
turn, activates PLC leading to an increase in IP3 and DAG (Thibonnier, 1992). 
However, cyclic AMP is not involved in the AVP receptor mechanism (Li et al., 
1992). 
Another possible mechanism by which AVP increases insulin release is 
through activation of PLAj, which has been accounted for the AVP-induced 
increase in Ca-"^ influx in the smooth muscle cell line A-JT^ (Thibonnier et al., 
1991). We used AC A, a PLA, blocker, in our experiments to determine if PL A, 
was involved in AVP's actions in RlNm5F cells. ACA (100 |aM) inhibits insulin 
secretion induced by glucose administration (Konrad et al., 1992). Our present 
results showed that ACA did not antagonize the AVP-induced increase in insulin 
release nor did it reduce the AVP-stimulated increase in [Ca^"]; (data not shown), 
suggesting that PLA, was not involved in AVP's actions in RINm5F cells. Further 
work is needed to determine what pathways, besides those mediated by PLC, 
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mediate AVP's actions in pancreatic beta-cells. U-73122 blocked the peak as well 
as second phase of the increase in [Ca^^]; in addition to its partial inhibition of 
insulin release. These findings suggested that activation of PLC but not PLA, is 
involved in the AVP-induced increase in insulin secretion in RINmSF cells. 
Ca^"^ is a major signal in the insulin secretion events (Martin et al., 1989; Li 
et al., 1992; Lu et al., 1993; Wollheim and Pozzan, 1984). In the present study, 
AVP still increased insulin secretion by 65% despite the fact that its increase in 
[Ca^""], was abolished by U-73122. Therefore, the Ca^'^-independent pathway(s) 
may have contributed to approximately 65% effect of AVP on insulin secretion in 
RINm5F cells. The AVP-activated Ca^^ independent pathway may not involve a 
rise in DAG, because U-73122 inhibits the PLC-elicited increase in DAG 
(Bleasdale et al., 1990; Bleasdale, 1992). Our observations raise concerns with 
regards to Ca^"" as the predominant second messenger in insulin secretion as 
mentioned by others (Findlay and Dunne, 1985; Wollhein and Pozzan, 1984). 
Further work is needed to determine the other signals, particularly the Car*-
independent ones that mediate the activation of V, receptors. 
In summary, U-73122 antagonized the AVP-activated IP3 and Ca""" dose-
dependently, but only partially inhibited the AVP-induced insulin secretion. We 
conclude that AVP activates multiple signal transduction pathways to trigger 
insulin secretion in RINm5F cells, one mechanism is via a Ca^^-dependent 
pathway, and the others maybe via Ca^'^-independent pathway(s). 
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Fig. 1. Effects of AVP on insulin secretion in RINmSF cells. Static incubation for 
15 min was performed to measure insulin secretion. Mean data ± S.E. (n=6) are 
shown. *p<.05, compared to the control group. 
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FLg. 2. Effect of U-73122 on AVP-induced insulin secretion in RINnaSF cells, (a) 
Static incubation for 15 min was performed to measure insulin secretion. U-73122 
was given 5 min before AVP (10 nM). (b) Incubation of suspended cells for 5 
min was performed. U-73122 was given 100 s before AVP (10 nM). Mean data ± 
S.E. (n=4) are shown. *p<.05, compared to the AVP (10 nM)-alone group. 
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Fig. 3. Effect of AVP on the peak [Ca^"]; increase in RINmSF cells. Mean data ± 
S.E. (n=5) are shown. *p<.05, compared to the control group. 
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Fig. 4. Effect of AVP on [Ca""], increase in RINmSF cells. Curve A shows AVP 
(100 nM) and curve B shows AVP (10 |iM). Arrow indicates the AVP 
adminstration. These are representative tracings, n=5. 
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Fig. 5. Effect of EGTA on AVP-induced increase in RINmSF cells. Curve 
A shows AVP (10 nM) alone as control. EGTA (2 mM) was given 30 s before 
AVP (10 nM) in curve B. Arrow indicates the AVP adminstration. These are 
representative tracings, n=5. 
46 
Fig. 6. Effect of nimodipine on AVP-induced [Ca"""], increase in RINmSF cells. 
Curve a showed AVP (10 nM) alone as control. Nimodipine 10"® M was given 30 
s before AVP (10 nM) in curve b. Arrow indicates the AVP adminstration. These 
are representative tracings, n=5. 
47 
100-1 
75-
50-
25-
4 8 
U73122, uM 
Fig. 7. Effect of U-73122 on AVP-induced peak [Ca^li increase in RINm5F cells. 
U-73122 was given 100 s before AVP (10 nM). Mean data ± S.E. (n=6) are 
shown. *p<.05, compared to the AVP (10 nM)-alone group. 
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Fig. 8. Effect of U-73122 on ionomycin-induced [Ca'""]! increase in RINmSF cells. 
Curve a shows ionomycin (100 nM) alone as control. U-73122 was given 100 s 
before ionomycin (100 nM) in curve b. Arrow indicates the ionomycin 
adminstration. These are representative tracings, n=5. 
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Fig. 9. Inhibition by U-73122 of AVP-induced production of IP3 from RINm5F 
cells. U-73122 was given 100 s before AVP (100 nM). The reaction was 
terminated after 10 s of AVP application. Mean data ± S.E. (n=4) are shown. 
*p<.05, compared to the AVP (100 nM)-alone group. 
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CHAPTER in THE CONTRIBUTION OF PHOSPHOLIPASE D TO AVP-
INDUCED INSULIN SECRETION FROM RINmSF CELLS, 
A PANCREATIC BETA CELL LINE 
A paper to be submitted to Life Science 
Ter-Hsin Chen, Bumsup Lee and Walter H. Hsu 
ABSTRACT 
We studied the effect of wortmarmin, an antifungal antibiotic that is a 
phospholipase D (PLD) inhibitor, on arginine vasopressin (AVP)-induced increases 
in insulin secretion and intracellular concentration ([Ca^^Jj) in RINmSF cells. 
Wortmannin (0.1 - 1 )j,M) inhibited AVP-induced increase of insulin secretion 
dose-dependently. Combination of wortmannin and U-73122, a phospholipase C 
(PLC) inhibitor, exerted an additive inhibition on AVP-induced increase of insulin 
secretion. However, wortmannin had no effect on AVP-induced increase of [Ca^"^];. 
These results suggested: (1) PLD is involved in AVP-induced increase of insulin 
secretion, (2) PLD does not influence AVP-elicited elevation of [Ca^"^]; and (3) 
both PLC and PLD participate in AVP-activated signal transduction independently. 
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INTRODUCTION 
Agonists, such as AVP, bradykinin (1), bombesin (2), and prostaglandin 
(3) respectively activate the GTP-binding protein-coupled receptors and thus 
stimulate the hydrolysis of phosphatidylcholine (PC) via PLC and PLD. This 
process leads to an increase in the production of diacylglycerol (DAG) and 
phosphocholine in one pathway and phosphatidic acid (PA) and choline in the 
other (4). In a previous study, we found that AVP increased insulin secretion from 
an insulin-secreting cell line RINm5F (5). However, this effect of AVP was only 
reduced, but not abolished, when PLC was completely inhibited. Our results 
suggested that part of AVP-stimulated insulin secretion is mediated by another 
system (5). Also, PLD activation in the stimulation of insulin release was found 
in the pancreatic islet cells (6,7). Therefore, we hypothesize that PLD mediates 
part of the AVP-stimulated insulin secretion. In this present study, we employed a 
PLD inhibitor, wortmannin, to prove or disapprove our hypothesis. Wortmarmin is 
an antifungal antibiotic isolated from Penicillium Wortmannin Klocker, and is 
widely used in the studies involving the PLD mechanism (8, 9, 10). The present 
study was performed in RINmSF cells, a clonal beta-cell line, that has been used as 
a model to study AVP-induced insulin secretion (5, 11, 12, 13). 
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METHODS 
Cell culture. RINmSF cells were maintained in RPMI 1640 contained 10% fetal 
bovine serum and aerated with 5% C02-95% air at 37°C as previous described (5). 
The cells were subcultured every 7 days, and all experiments were performed with 
cells in passages 43-53. 
Insulin release. RINmSF cells were plated into 24-well costar plates at 2 x 10' 
cells/well and grown for 5 days. Growth medium was removed and the monolayer 
cells were washed with modified Krebs-Ringer bicarbonate buffer (KRB) 
containing (in mM): 136 NaCl, 4.8 KCl, 1.2 CaClj, KH2PO4, 1.2 MgSO^, 5 
NaHCOj, 10 Hepes, 4 glucose and 0.1% bovine serum albumin, pH 7.4. The cells 
were then preincubated for a 30-min basal period at 37°C, followed by a 10-min 
incubation in KRB with the test agent. When needed, U-73122 was given 5 min 
before the administration of AVP or KCl. The supemantants were collected for the 
radioimmunoassay (RIA) of insulin as previously described (14). 
Measurement of [Ca^"^];. To measure [Ca^"^]; in all suspension, 30x10' cells were 
loaded with 2 nM of fura-2 acetoxymethylester (AM) in KRB for 30 min at 37°C. 
The loaded cells were washed and kept at 24°C until used. Cells were resuspended 
at a concentration of lOVml and a l.S-ml aliquot was used for [Ca^"^]; determination 
at 24°C. The 340/380 nm fluorescence ratios were monitored using a SLM-8000 
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Fluorescence spectrophotometer (SLM, Urbana, IL). The [Ca^^Jj was calibrated 
after the cell lysis as described previously (14). When needed, U-73122 was given 
100 s before the administration of AVP or KCl. 
Statistical analysis. Results are presented as mean ± SE. Differences between 
means were determined by using the Student's t test. The significance level was 
set at P<0.05. 
Materials. The following were used: fura-2AM (Molecular Probes, Eugene, OR); 
AVP and wortmannin (Sigma Chemical Company, St. Louis, MO); and U-73122 
(Biomol Research Laboratory, Plymouth Meeting, PA). 
RESULTS 
Effect of wortmannin in A VP-induced increase of insulin secretion and fCa^^^l: in 
RINm5F cells. 
Pretreatment with wortmannin (0.1-1 |aM) for 5 min inhibited AVP (0.1 
p.M)-induced insulin secretion dose-dependently (Fig. 1). Wortmannin alone did 
not change basal insulin release (data not shown). At the highest dose studied, 
wortmannin (1 |iM) inhibited 0.1 jxM AVP-induced insulin release by 
approximately 30%. However, pretreatment with wortmannin (luM) for 5 min 
did not affect KCl (10 mM)-induced insulin secretion (data not shown). Although 
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[Ca^^Jj is the major signal to trigger insulin secretion (15), we found that 
wortmannin (1 |aM) did not change AVP-elicited increase in [Ca^^], (data not 
shown). 
Effect of the wortmannin - U-73122 combination in A VP-induced increase of 
insulin secretion in RINmSF cells. 
In the previous study we found that the PLC inhibitor U-73122 partially 
inhibited AVP-induced insulin secretion and suggested that another component may 
be involved in AVP-induce insulin secretion (5). In the present study, pretreatment 
of RINmSF cells with wortmannin and U-73122 (8 |aM) caused additive inhibition 
on AVP-induced insulin release (Fig. 2). As mentioned before, wortmannin (1 
jiM) inhibited AVP-induced insulin release by 30%, and U-73122 (8 [JM) inhibited 
AVP-induced insulin release by approximately 50%. When wortmannin (1 |iiM) 
and U-73122 (8 |iM) were combined, they inhibited AVP-induced insulin release 
by approximately 80%. 
DISCUSSION 
Phospholipid hydrolysis may play an important intermediary role in the 
stimulus-secretion coupling of insulin release (16). Physiologic agonists activate 
phospholipases and produce different lipid messengers which amplify insulin 
secretion (17). In our previous study, we found that AVP-induced insulin secretion 
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may be mediated by multiple signal transduction pathways (5). The downstream 
effectors, such as PLC and PLAj, have beeen investigated (5). Another possible 
candidate in the AVP-induced signal transduction pathway is PLD. The result of 
the present study suggested that PLD is involved in AVP-induced insulin secretion. 
Our results further suggested that PLC and PLD are independent components in the 
AVP's action, because the PLD inhibitor, wortmannin, and PLC inhibitor, U-
73122, caused an additive inhibition on AVP-induced insulin secretion. This is 
consistent with the finding in liver cells (18, 19). However, the interaction 
between PLC and PLD is different in different systems. In some systems, 
activation of PLD is dependent on activation of PLC (21, 22, 23, 26). In other 
systems, activation of PLD is independent of activation of PLC (18, 19). AVP 
activates PLC and PLD in several models, such as hepatocytes (20), myoblasts 
(21), Swiss 3T3 fibroblasts (22), smooth muscle cells (23), Leydig cells (24), 
mesangial cells (25). Our finding suggested that AVP increases insulin secretion in 
RINm5F cells by activating PLC and PLD independently. 
Ca^"" plays a central role in cell signaling, both as a second messenger and 
as a regulator of signaling effector enzymes (25). In RINm5F cells, AVP elicited 
a peak followed by a sustained rise in [Ca^'^]) (5). The peak increase of [Ca^^]j is 
mediated by the release of Ca^^ from intracellular Ca^^ stores and the sustained rise 
in [Ca^^^jj is maintained by influx of extracellular Ca^^ (5). The sustained rise in 
[Ca-^^lj is essential for the activation of PLD (26). However, the effect of PLD on 
[Ca^""]) is not well imderstood. In the present study, we found that the PLD 
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inhibitor wortmannin inhibited AVP-induce increase in insulin secretion but did not 
influence AVP-elicited increase in [Ca^"];. This result suggested that PLD may be 
only involved in the machinery of insulin secretion but not in the elevation of 
[Ca*^]}. PLD catalyzes the formation of PA and DAG (4). Additional studies are 
needed to further characterize the downstream signal transduction of PLD in the 
regulation of insulin secretion or the role of PA and DAG on insulin secretion. 
Wortmaniun may exert a specific inhibitory effect on the activation of PLD 
in beta-cells. Although wortmannin also is a potent inhibitor of 
phosphatidylinositol 3 (PI3)-kinase inhibitor (27), PI3-kinase plays a negative feed­
back role on insulin secretion in the pancreatic beta-cell (28). If wortmannin had 
inhibited both PLD and PI3-kinase in the present study, its real contribution to 
AVP's action would have been underestimated. Therefore, our finding suggested 
that PLD activation contributes to AVP-induced insulin secretion. 
We concluded that in RINmSF cells: 1) PLD was involved in AVP-induced 
increase of insulin secretion, 2) PLD did not influence AVP-elicited elevation of 
[Ca^^]j, and 3) both PLC and PLD participated in the AVP-activated signal 
transduction independently. 
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Fig. 1. Effect of wortmannin in AVP-induced increase of insiilin release in 
RINmSF cells. Static incubation for 10 min was performed to measure insulin 
release. Wortmannin was given 5 min before the administration of AVP (0.1 |iM). 
Mean data ± SEM are shown (n=4). *p<0.05, compared with the control group. 
61 
Insulin secretion 
(AVP control=100%) 
0 25 50 75 100 
1 1 1 1 1 
WMN 03 |iM -
WMN 1 |iM -
U73122 8^M-
WMN 0.3 |iM + U73122 8 |iM • 
WMN 1 nM + U73122 8 |J.M -
11 
H 
Fig. 2. Effect of wortmannin (WMN) - U-73122 combination on AVP-induced 
increase of insulin secretion and in RINmSF cells. The experimental condition was 
the same as in Fig. 1. U-73122 was given 5 min before the administration of AVP 
(0.1 |iM). Mean data ± SEM are shown (n=4). Each group is different from 
others. 
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CHAPTER IV THE INHIBITORY EFFECT OF PROTEIN KINASE C IN 
ARGININE VASOPRESSIN-INDUCED INSULIN SECRETION AND Ca^* 
MOBILIZATION IN A PANCREATIC BETA-CELL LINE RINmSF 
A paper to be submitted to the Journal of Pharmacology and Experimental 
Therapeutics 
Ter-Hsin Chen, Bumsup Lee and Walter H. Hsu 
ABSTRACT 
The role of protein kinase C (PKC) in arginine vasopressin (AVP)-induced 
insulin secretion was investigated in RINmSF cells. Ro 31-8220, a specific PKC 
inhibitor, dose-dependently potentiated AVP-induced insulin secretion and elevation 
of intracellular Ca^"^ concentration ([Ca^^^Ji) when givn 30 min before AVP 
administration. However, Ro 31-8220 did not enhance KCl-induced insulin 
secretion or elevation of [Ca^"^];. In Ca^^- or Na^-free medium, Ro 31-8220 did not 
change AVP-induced elevation of [Ca^^]j. Pretreatment with an analog of 
diacylglycerol, l-Oleoyl-2-acetyl-sn-glycerol (GAG) for 5 min, inhibited AVP-
induced insulin secretion dose-dependently, and slightly but significantly inhibited 
AVP-induced elevation of [Ca^^Jj. GAG alone did not change basal insulin 
secretion or [Ca^"^];, nor did it change KCl-induced insulin secretion or elevation of 
[Ca^, 
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We conclude that: 1) PKC may serve as a negative regulator in RINmSF 
cells to diminish AVP-induced insulin secretion, 2) PKC may decrease AVP-
induced insulin secretion at least partly by inhibiting Ca^* channels, and 3) PKC 
may not influence AVP-induced intracellular Ca^"^ release. 
INTRODUCTION 
PKC is activated by diacylglycerol (DAG) which is generated via the 
receptor-activated phospholipases by a number of hormones and neurotransmitters 
such as vasopressin, oxytocin, acetylcholine and bombesin (Ashcroft, 1994). PKC 
has been purified in beta-cells and exists as a monomer of 80 kD (Lord and 
Ashcroft, 1984). There are 10 sub-types of Ca^^-, phospholipid-dependent PKC 
that have been identified, and at least two isoforms (a, P) are known to be present 
in the pancreatic beta-cells (Ashcroft, 1994; Wilkinson and Hallam, 1994). Also a 
number of endogenous substrates for PKC have been identified in rodent pancreatic 
beta-cells (Hughes and Ashcroft, 1988). 
In the mouse islet and two clonal pancreatic beta-cell lines (HIT and 
RINmSF) activation of PKC may stimulate or inhibit insulin secretion depending 
on the experimental conditions (Gao et al., 1994). Some reports showed that PKC 
increased insulin secretion (Monaco et al., 1988; Yada et al., 1989), whereas others 
concluded that PKC played a negative feedback role in insulin secretion (Li et al., 
1991). One carmot draw a clear-cut conclusion from these contradictory findings 
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with regard to the role of PKC in pancreatic beta-cells. The reasons for the 
discrepancies among these reports are not known; however one possibility is that 
the tools used in the investigation of PKC may have other effects (Wilkinson and 
Hallam, 1994). For example, PKC inhibitors may have additional effects 
independent of the PKC inhibition. Also, prolonged exposure to PKC activators 
may cause downregulation of PKC. Furthermore, some PKC isoforms, such as 
atypical PKC, are not downregulated by the pretreatment vWth phorbol-12-
myristate-13-acetate (PMA) and the absence of downregulation by phorbol esters 
does not exclude the participation of PKC (Selbie et al., 1993). Phorbol esters, the 
activators of PKC, usually produce a strong and prolonged activation of PKC when 
compared with the transient activation of PKC generated by DAG analogs 
(Wilkinson and Hallam, 1994). These existing pharmcological tools for studying 
PKC may make the interpretation of findings more difficult. Recently, a series of 
derivatives of staurosprine such as Ro 31-8220 have been developed as potent and 
specific PKC inhibitors (Davis et al., 1989). 
In the present study, we used a highly specific PKC inhibitor Ro 31-8220 
and a DAG analog OAG to investigate the role of PKC on AVP-induced insulin 
secretion and Ca^^ mobilization in RINmSF cells. 
65 
METHODS 
Cell Culture. RINm5F cells were maintained in RPMI 1640 containing 10% fetal 
bovine serum and aerated with 5% €02-95% air at 37°C as previous described 
(Chen et al., 1994). All experiments were performed using passages 43-53. 
Insulin Secretion. RINm5F cells were plated into 24-well Costar plates at 2 x 10^ 
cells/well and grown for 5 days. Growth medium was removed and the monolayer 
cells were washed v^dth modified Krebs-Ringer bicarbonate buffer (KRB) 
containing (in mM): 136 NaCl, 4.8 KCl, 1.2 CaClj, KH2PO4, 1.2 MgS04, 5 
NaHCOj, 10 Hepes, 4 glucose and 0.1% bovine serum albumin, pH 7.4. The cells 
were then preincubated for a 30-min basal period at 37°C, followed by a 15-min 
incubation in KRB with the test agent. The Ca^'^-free KRB was supplemented with 
10 [iM [ethylenebis (oxyethylenenitrilo)] tetraacetic acid (EGTA). When needed, 
Ro 31-8220 was given 30 min before the administration of AVP or KCl. The 
supemantants were collected for the radioimmunoassay (RIA) of insulin (Hsu et 
al., 1991). 
Measurement of [Ca^"^];. To measure [Ca^^]; in the cell suspension, 30 x 10® cells 
were loaded with 2 |aM of fura-2 actoxymethylester (AM) in KRB for 30 min at 
37''C. The loaded cells were washed and kept at 24°C until use. Cells were 
resuspended at a concentration of lOVml and 1.5-ml aliquots were used for [Ca^"^]; 
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determination at 24°C. The 340/380 nm fluorescence ratios were monitored using 
a SLM-8000 Fluorescence spectrophotometer (SLM, Urbana, IL). The [Ca^^^Jj was 
calibrated after cell lysis as previously described (Hsu et al., 1991). When need, 
Ro 31-8220 was given 30 min before the administration of AVP or KCl. 
Statistical Analysis. Results were analyzed by using the Student's t test for paired 
and unpaired values. The significance level was set at P<.05. 
Materials. The following were used: Nimodipine (Research Biochemicals 
International, Natick, MA); Fura-2AM (Molecular probes, Eugene, OR); OAG 
(Sigma Chemical Co., St. louis, MO); SKF 96365 (Biomol Co., Plymouth 
meeting, PA); Ro 31-8220 (Roche Products, Hertfordshire, U.K.) 
RESULTS 
Enhancement bv Ro 31-8220 of AVP-induced increase of fCa^^l, in RINmSF cells. 
AVP induced a sharp and transient increase in [Ca^^]j which was followed 
by a lower sustained phase in [Ca""]; (Fig. 1). Ro 31-8220 (1-10 |xM) alone did 
not change [Ca^"^]; (data not shown). After the pretreatment with the PKC inhibitor 
Ro 31-8220 (1-10 |i.M), the sustained phase of AVP (0.1 |aM)-induced increase of 
[Ca^^]j was enhanced dose-dependently (Fig. 1). Ro 31-8220 (10 ^M) did not 
change the AVP (0.1 ^M)-induced transient increase of [Ca^"^]; (data not shown). 
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In a Ca^^'-free medium, AVP (0.1 nM) only induced a transient increase of [Ca*"]; 
which is due to the Ca^'' release of Cs?* from intracellular stores. The pretreatment 
with Ro 31-8220 (10 |xM) did not enhance KCl (10 inM)-induced increase in 
[Ca^""]! (Fig. 2). KCI (10 mM) increased [Ca^^]; by depolarizing the membrane 
potential and opening voltage-dependent Ca^"^ channels. 
The sustained phase of AVP-induced increase of [Ca^""]; is mediated by Csr* 
influx through Ca^"" channels (Chen et al., 1994). In order to determine if the 
enhancement by Ro 31-8220 of AVP-induced increase in [Ca^""]) was due to 
opening of Ca^^ channels, SKF 96365, a receptor-operated Ca^" channel (ROC) 
blocker, and nimodipine, a voltage-dependent Ca^^ channel blocker, were applied. 
Both of them significantly reduced Ro 31-8220 (10 |iM)-elicited enhancement (Fig. 
3). 
Enhancement by Ro 31-8220 of AVP-induced increase of insulin secretion in 
RlNmSF cells. 
Pretreatment with Ro 31-8220 (1-10 pM) for 30 min enhanced AVP (0.1 
|iM)-induced insulin secretion dose-dependently (Fig. 4a). The resuhs of the 
[Ca^^Jj experiment suggested that Ro 31-8220 enhanced the AVP-induced sustained 
phase of the [Ca^"^]; increase. In order to test the mechanism of the enhancement in 
insulin secretion, we used Ca^^-free KRB in the insulin secretion experiment. Ro 
31-8220 (10 t^M) still enhanced AVP (0.1 |j,M)-induced insulin secretion in the 
Ca^"^ free condition (Fig. 4b). But the amplitude of enhancement was reduced. 
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The basal insulin secretion (34 ± 5 ng/min/well) in the absence of extracellular 
Ca^^ was approximately 1/5 of the basal insulin secretion (150 ± 12 ng/min/well) in 
the presence of extracellular Ca^"^. 
Nimodipine (1 |iM), an L-type Ca^"^ charmel blocker, reduced but did not 
abolish the stimulatory effect of Ro 31-8220 on AVP-induced insulin secretion 
(Fig. 5). The pretreatment with Ro 31-8220 (10 |iM) did not enhance KCl (10 
mM)-induced insulin secretion (data not shown). 
Effect of OAG on AVP-induced increase of FCa^^l; in RINm5F cells. 
Stimulation of the cells with the membrane-permeable DAG analog OAG 
(30 ixM) did not change the basal [Ca^""]! (data not shown). Pretreatment with 
OAG (30 |aM) produced a small but significant decrease in AVP-induced increase 
of [Ca^^li [AVP : AVP + OAG = 131.5 ± 4.3 nM : 149.2 ± 5.1 nM, p<0.05, (n=4)] 
(Fig. 6). In the Ca^'^-free medium, OAG (30 ^iM) did not change the AVP (0.1 
^M)-induced transient increase of [Ca^"^], (data not shown). Pretreatment with 
OAG (30 |J.M) did not influence KCl (10 mM)-induced increase in [Ca^^]j (data not 
shown). 
Inhibition by OAG of AVP-induced increase of insulin secretion in RINmSF cells. 
OAG (30 |iM) did not change basal insulin secretion (data not shown). 
Pretreatment with OAG (1-30 |xM) for 5 min inhibited AVP (0.1 |aM)-induced 
insulin secretion dose-dependently (Fig. 7), although OAG (30 |jiM) only slightly 
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reduced the AVP-induced increase of [Ca^""]; (Fig. 6). Pretreatment with OAG (30 
|xM) did not change KCl (10 mM)-induced insulin secretion (data not shown). 
DISCUSSION 
The role of PKC in beta-cells has been studied with clonal beta-cell lines 
and pancreatic beta-cells for a decade (Gao et al., 1994). However, most of the 
findings are difficult to interpret. Even in an insulin secreting cell line (RINmSF 
cells) and normal pancreatic beta-cells, PKC performs differently in response to 
different PLC-mediated stimulators. The limitation in the study of PKC is the 
lack of specific investigating tools. The members of the family of PKC have 
different characteristics, such as Ca^"" sensitivity/insensitivity, and phorbol ester 
sensitivity/insensitivity (Wilkinson and Hallam, 1994). Phorbol esters are 
frequently used as a tool to study PKC. Phorbol esters stimulate PKC acutely but 
overnight incubation of them inhibits PKC (Ashcroft, 1994). Phorbol esters may 
cause some effects such as inducing Ca^" influx which are not related to PKC 
activation (Wilkinson and Hallam, 1994). A series of potent and highly selective 
inhibitors have been developed based on the structure of staurosporine which is a 
non-specific PKC inhibitor (Davis et al., 1989). Recently Ro 31-8220, a specific 
PKC inhibitor, was used in the study of the cluster of differentiation (CD) 4- and 
CD 8- induced intracellular signalling (Ravichandran and Burakoff, 1994) and 
glucose-stimulated insulin secretion in the rat islets (Persaud and Jones, 1995). In 
70 
the present study, we applied Ro 31-8220 to investigate the role of PKC in AVP-
induced insulin secretion in RINmSF cells. We found that Ro 31-8220 enhanced 
AVP-induced insulin secretion and elevation of [Ca^^];. This result suggested that 
PKC negatively regulates AVP-induced insulin secretion and elevation of [Ca^"]!-
This finding is consistent with that in RINmSF cells and normal mouse pancreatic 
beta-cells in that PKC plays a negative feedback role on the signal transduction 
mechanisms involving PLC (Gao et al., 1994, Li et al., 1990). 
Ca^'^-free medium was used to further investigate the relationship of insulin 
secretion and [Ca^"^]; in Ro 31-8220-elicited enhancement. In the absence of 
extracellular Ca^"^, Ro 31-8220 failed to change AVP-induced increase in [Ca"^],. 
This finding suggested that PKC decreases AVP-induced insulin secretion by 
inhibiting Ca^^ influx. The Ca^"^ influx may be mediated by Ca^"" channels or the 
NaVCa^^ exchanger. However, in the Na'^-free medium, Ro 31-8220 failed to 
change AVP-induced Ca^"^ influx (data not shown). These results suggested that 
PKC inhibits Ca^" influx through Ca^"^ channels. In mouse pancreatic beta-cells, 
PKC plays a negative role in the regulation of VDCCs (Arkhammar et al, 1994). 
PKC inhibits the AVP-induced increase of [Ca^^]; in HIT cells (Hughes et al., 
1992). PKC activation is associated with a lowering of intracellular Ca^"^ in HIT 
cells (Hughes et al., 1989). Also, activation of PKC inhibits T cell receptor 
(TCR)-mediated Ca^"^ influx in HPB-ALL T cells (Shivnan and Alexander, 1995). 
In this study, we found the L-type Ca^" channel blocker, nimodipine, reduced but 
did not abolish Ro 31-8220-enhanced AVP-induced Ca^^ influx. However, SKF 
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96365, a blocker of ROC, caused greater inhibition than nimodipine on Ro 31-
8220's effect. This suggested that PKC inhibits not only VDCCs but also ROC. 
The use of phorbol esters and DAG analogs to mimic the responses 
stimulated by physiological ligands has provided the evidence to support the 
potential role of PKC in ligand-induced cellular responses (Wilkinson and Hallam, 
1994). In this study we used a DAG analog, OAG, to mimic the effect of DAG. 
We found that OAG (30 |iM) had no effects on basal insulin secretion, but it 
inhibited AVP-induced insulin secretion. This finding suggested that PKC 
negatively regulates insulin secretion. Acute treatment with phorbol 12-myristate 
13-acetate (PMA) ether enhanced (Monaco et al., 1988) or abolished (Li et al., 
1991) AVP-induced insulin in RINmSF cells, but both studies showed that PMA 
inhibited AVP-stimulated production of inositol phosphate (Monaco et al., 1988, Li 
et al., 1991). Because phorbol esters stimulate insulin secretion by membrane 
depolarization and increase [Ca^"^]; in RINmSF cells (Yada et al., 1989) through 
mechanisms independent of PKC activation, this makes the interpretation of the 
PMA resuhs difficult. As mentioned earlier, PKC may inhibit Ca^"^ channel 
activity (Arkhammar et al., 1994); however, OAG only slightly reduced AVP-
induced increase of [Ca^""]; while it caused a greater inhibition on insulin secretion. 
Perhaps the effect of AVP-activated PKC on Ca^"^ chaimels reached near maximum 
in the present study (as seen in the results of the Ro 31-8220 experiment). Under 
this circumstance, OAG may have caused a small activation of PKC and a small 
inhibition of AVP-induced increase of [Ca^^Jj. More activation of PKC did slightly 
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enhance the inhibition on Ca?* channels. 
An alternative explanation would be that PKC inhibits partially insulin 
secretion through a Ca^^-independent pathway in pancreatic beta cells. 
In conclusion, our findings suggested that: 1) PKC is a negative regulator in 
A VP's action, 2) PKC inhibits the Ca^^ channels, thereby decreasing insulin 
secretion, and 3) PKC has no effect on AVP-induced intracellular Ca^"^ release. 
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Ro 31-8220, .LLM 
Fig. 1. Effect of Ro 31-8220 on AVP-induced sustained phase of increase in [Ca^"^]; 
in RINmSF cells. Ro 31-8220 was given 30 min before AVP (0.1 |j.M). [Ca^*]; 
was measured 150 s after the administration of AVP. Mean ± S.E. (n = 4) are 
shown. *P<.05, compared to the AVP (0.1 ^M) alone group. 
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Ro+KCl 
Fig. 2. Effect of Ro 31-8220 on A VP (a)- and KCl (b)-induced increase in [Ca^"];. 
Ro 31-8220 (10 |iM) was given 30 min before the administration of KCl (10 mM) 
or AVP (0.1 |iM). These are representative tracings of four experiments. 
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Fig. 3. Effect of SKF 96365 (a) and nimodipine (b) on Ro 31-8220 enhancement 
of AVP-induced increase of [Ca^""];. Ro 31-8220 was given 30 min before the 
administration of AVP. SKF 96365 (30 |iM) or nimodipine (1 |iM) was given 100 
s before the administration of AVP. These are representative tracings of four 
experiments. 
80 
«_ii 
"3 
V )  w  
s a 
tn 2-1 5 > 
< 
400 T 
300-
200-
100-
* 
A 
X 3 10 
Ro-31.8220, fiiM 
5 o 
:s ^ £ IT 
4> U 
. c §  S u 
3 
" a. 
£> 
400-, 
300-
200-
100-
* 
mCT? 
Ro 31-8220, ^ 
* 
?»7: 
—T— 
10 
Fig. 4. Effect of Ro 31-8220 on AVP-induced insulin secretion. In the presence 
(a) and absence (b) of extracellular Ca^" static incubation for 10 min were 
performed to measure insulin secretion. Ro 31-8220 was given 30 min before 
AVP (0.1 |iM). Mean data ± S.E. (n = 4) are shown. *P<.05, compared to the 
AVP (0.1 |iM) alone group. 
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Fig. 5. Effect of nimodipine on the enhancement of Ro 31-8220 on AVP-induced 
increase of [Ca'"];. Ro 31-8220 was given 30 min before the administration of 
AVP. Nimodipine (Nim) (1 |iM) was given 5 min before the administration of 
AVP (0.1 jiM). Mean data ± S.E. (n = 4) are shown. *P<.05, compared to the 
control (basal) group. 
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Fig. 6. Effect of OAG on AVP-induced [Ca^"]; increase. OAG (30 jiM) was given 
30 s before the adniinistration of AVP (0.1 fiM). These are representative tracings 
of four experiments. 
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Fig. 7. Effect of OAG on AVP-induced insulin secretion. Static incubation for 10 
min was performed to measure insulin secretion. OAG was given 5 min before 
AVP (0.1 |aM). Mean data ± S.E. (n = 4) are shown. *P<.05, compared to the 
AVP (0.1 ^M) alone group. 
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CHAPTER V GENERAL DISCUSSION 
The resuhs presented in this dissertation have already been discussed in the 
Discussion section of each chapter. In this chapter, the delineation of these 
chapters will be discussed in general. 
AVP-induced multiple signal transduction pathways in pancreatic beta-cells 
The hormone or neurotransmitter that carries information into the cells is 
received by the cells when it binds to a specific receptor. This receptor then 
mediates the activation of a secondary process to increase the concentration of the 
second messenger in the cytosol of the cell. The cascade of signal transduction is 
amplified in each step toward downstream effectors (Offermanns and Schultz, 
1994). In the pancreatic beta-cell, AVP affects multiple signal transduction 
pathways (Gao and Henquin, 1993). When AVP binds to the vasopressin receptor, 
it activates the G protein which in turn activates PLC and PLD. In some other cell 
models AVP also activates PLAj (Briley et al., 1994), but this phenomenon was 
not seen in RINmSF cells. Activation of PLC hydrolyzes the PIP2 to generate IP3 
and DAG. IP3 releases Ca*^ from intracellular cellular stores, which in turn 
induces Ca^"" influx. This is so called the "capacitative" mechanism (Putney, 1990). 
However, the mechanism to cause Ca^ influx after the rapid intracellular Ca^"" 
release is still not well-understood and is under investigation (Fasolate et al., 1994). 
According to the findings of this study, the capacitative mechanism is involved in 
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AVP-induced influx, and part of the Ca^" influx is mediated through VDCCs. 
Similar observations have been found in several other cell models such as 
chromaffin cells and pituitary cells (Fasolate et al., 1994, Zheng et al., 1995). 
Even though AVP activates multiple signal transduction pathways in the 
pancreatic beta-cell, the increase of [Ca^"^], is still the major signal for triggering 
insulin release. When extracellular Ca^"" is absent, the AVP-induced insulin release 
is dramatically inhibited. This is consistent with other reports in beta cells 
(Ashcroft et al., 1994). Other endocrine cells such as chromaffin cells have similar 
dependency on extracellular Ca""" (Augustine and Neher, 1994). In several systems, 
a Ca^'^-independent exocytosis exists (Arispe et al., 1992, Steuenkel and Nordmann, 
1993). In the pancreatic beta-cell, it is generally accepted that the Ca-^-dependent 
component is the major factor in the regulation of insulin release (Ammala et al., 
1993). We found that the presence of extracellular Ca^"^ is essential for AVP-
induced insulin release, but part of the insulin release induced by AVP was 
independent of the increase of [Ca^"];. This suggested that some other intracellular 
effectors operate to trigger insulin release when the [Ca^""]; is at basal level. It is 
possible that a Ca'^'-independent component is involved in AVP-induced insulin 
secretion. However, this issue is still debatable, because it is possible that the 
concentration of intracellular Ca^"" under the plasma membrane was heterogenous 
and underwent changes which were not detected by the technique applied in this 
study. Further investigation is needed to study AVP-induced increase in [Ca-"]! by 
using specific tools which can determine the local changes of the [Ca^"]; (Etter et 
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al., 1994), or using confocal microscopy which can determine the 3-D dimension 
of the cell structure. These advanced tools will provide more precise measurement 
in [Ca^^Jj and reveal the accurate changes of [Ca^"]) in a specific region of the cell. 
The contribution of phospholioases to AVP-induced insulin secretion 
In pancreatic beta-cells, different receptors which are coupled to the 
protein, also activate multiple signal transduction pathways (Regazz et al., 1990). 
The resuhs of this study suggest that PLC contributes to approximately 50% of the 
AVP-induced insulin secretion and is the major cytosolic effector in AVP's action. 
However, PLAj was not involved in the AVP-induced insulin secretion from 
RINmSF cells. The activation of PLD contributes to approximately 30% of AVP-
induced insulin secretion. Similar observation were found in other endocrine 
systems, such as chromaffin cells (Holbrook et al., 1992). PLD has become more 
significant in signal transduction, because studies revealed that the products from 
the catalysis by PLD, PA and DAG, have significant effects in the cellular 
response (Exton, 1994, and Tronchere. et al., 1994). PLD activation generates PA 
that is converted to DAG by the action of PA phosphohydrolase. PA has been 
demonstrated to increase insulin secretion in pancreatic islets and RINmSF cells 
(Rustenbeck et al., 1994). However, the mechanism by which PA increases insulin 
secretion is still not clear. Atypical PKC is regulated by PA but not DAG 
(Dimitrijevic et al., 1995). It is likely that the physiological effect of PA, and thus 
PLD activation, is mediated through the activation of PKC or some unknown 
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mechanisms (Wakelam et al., 1993) 
Although attention has been focused on the actions of the products of 
phospholipases, it should be recognized that activation of phospholipases also 
causes changes in the phospholipid content of their target membranes (Exton, 
1994). If the action of phospholipases was localized to a particular area of the 
membrane, the physical and chemical property of the membrane could be altered. 
Such changes in certain secretory vesicles or constitutive membranes may be 
involved in the regulation of secretion and neurotransmission. Also, it could 
regulate the maintenance of the subcellular membranes. Lipid changes in the 
plasma membrane resulting from the action of phospholipases may be responsible 
for some effects of agonists on the membrane-dependent phenomena (Exton, 1994). 
The role of PKC in the regulation of AVP-induced signal transduction 
Evidence has emerged over the past decade to suggest that PKC is a 
widespread family of kinases responsible for many diverse and critical cellular 
functions (Wilknson and Hallam, 1994). Exocj^osis is regulated by a dynamic 
balance between protein phosphorylation and dephosphorylation. In the pancreatic 
beta-cells, an increase in protein phosphorylation by an exogenously applied 
activators of PKC enhance insulin secretion (Ammala et al., 1994). However, 
receptor-mediated activation of PKC is controversial. A number of highly-specific 
tools have been developed in recent years (Davis et al., 1989) and as a resuh, the 
role of PKC in the cellular response is being re-evaluated. In this study, Ro 31-
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8220, a specific PKC inhibitor, enhanced AVP-induced insulin secretion and the 
sustained phase of the increase [Ca^^j. This suggested that PKC is a negative 
regulator in the action of AVP. Similar results were observed in bradykinin's 
action in pancreatic beta cells (C. Yang's unpublished data). However, Ro 31-
8220 inhibits glucose-stimulated insulin secretion in rat islets (Persaud and Jones, 
1995). It was speculated that phorbol ester-insensitive isoforms of PKC (atypical 
PKCs) are involved in glucose-stimulated insulin secretion (Persaud and Jones, 
1995). It has been suggested that PKC plays a dual role in cellular responses 
(Nishizuka, 1992). Therefore, PKC may play multiple roles and thus interacts at 
different sites in the complex series of events constituting the beta-cell signal-
transduction pathways (Arkhammar et al., 1994). We speculate that glucose and 
AVP, respectively, activate different signal transduction pathways and different 
subtypes of PKC. However, further investigation by characterizing the subtypes of 
\ 
PKC in AVP- and glucose-induced insulin secretion will provide answers to this 
question. 
The target of PKC is a 145-kDa cytoplasmic protein that is essential for the 
Ca^'^-dependent secretion in the stimulation by PKC and has been identified in a 
number of neuroendocrine cells, including RINmSF cells (Nishizaki et al., 1992, 
Walent et al., 1992). Also, the VDCC is one of PKC-regulated targets 
(Arkhammar et al., 1994). PKC inhibits the AVP-induced [Ca^"]; in HIT cells 
(Hughes et al., 1992), and PKC activation is associated with a lowering of 
intracellular Ca^"^ in HIT cells (Hughes et al., 1989) and mouse pancreatic beta-
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cells (Arkhammar et al., 1994). In the present study, we propose that PKC 
activation is involved in the inhibition of Ca^^ influx which contributes to AVP-
induced increase of [Ca^^^Jj in the pancreatic beta-cell. AVP-induced Ca^* influx is 
mediated through VDCCs and ROCs (Chen et al., 1994). Our results suggested 
that PKC may inhibit both types of Ca^"^ channels. In HPB-ALL T cells, PKC 
activation inhibhs agonist-stimulated Ca^^ influx but not intracellular Ca^"" release 
(Shivnan and Alexander, 1995). The resuhs indicate that PKC inhibits Ca^^ influx. 
However, there is no specific ROC blocker; for example, SKF 96365 at the 
concentration used in the study also inhibits VDCCs. Without a specific ROC 
blocker, we can not clearly characterize this PKC-regulated effect. In our control 
experiments, inhibition of PKC did not enhance KCl-induced increase of [Ca^^Jj 
which is mediated by Ca^"" influx through VDCCs. This suggested that there are 
some interactions between the PLC-mediated signal transduction and PKC. If the 
Ca^^ influx is not induced by PLC mediated signal transduction, the negative 
regulation by PKC would not be real. 
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CHAPTER VI GENERAL SUMMARY 
The present study was undertaken to investigate the mechanism by which 
AVP increases insulin secretion in RINmSF cells, a clonal beta-cell line. A 
specific PLC inhibitor, U-73122, and a PLAj inhibitor, ACA were used in the 
present study. AVP (0.1-100 nM) increased insulin secretion and dose-
dependently. Moreover, U-73122 (2-8 |j,M) inhibited the AVP-induced increases in 
the intracellular concentration of IP3 and [Ca^""]; dose-dependently. At 8 (iM, U-
73122 abolished AVP's effect on IP3 and [Ca^"^];, but it only reduced the AVP-
induced increase in insulin secretion by 35%. In contrast, 8 |j,M U-73122 did not 
reduce the ionomycin (a Ca^"" ionophore, 100 nM)-induced increase in [Ca""^]j. The 
discrepancy between the results of [Ca^^^Jj and insulin secretion may be due to the 
multiple signal transduction pathways associated with the activation of AVP 
receptors, specifically the Ca^^-independent pathway. The phospholipase Aj 
inhibitor, ACA (100 |xM) did not antagonize the AVP (10 nM)-induced increase in 
insulin release. These resuUs suggested: 1) U-73122 blocks PLC activities but fails 
to block other signal transduction pathways that trigger insulin secretion in these 
cells, and 2) AVP increases insulin release from RINmSF cells through both the 
PLC mediated Ca^'^-dependent and Ca^'^-independent pathways. 
Based on the above results, we speculated that PLD was involved in a Ca^^-
independent pathway of the AVP-induced insulin secretion. 
To characterize the role of PLD in AVP's action, we investigated the effect 
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of the antifungal antibiotic wortmannin, a PLD inhibitor, on AVP-induced 
increases in insulin secretion and [Ca^""]; in RINmSF cells. Wortmannin (0.1-1 
|iM) inhibited AVP-induced increase of insulin secretion dose dependently. The 
combination of wortmannin and U-73122, had an additive inhibition on the AVP-
induced insulin secretion. However, wortmannin failed to change the AVP-induced 
increase of [Ca^^^Jj. These results suggested: (1) activation of PLD stimulated at 
least partially the AVP-induced increase of insulin secretion, (2) PLD did not 
influence the AVP-elicited elevation of [Ca^^]; and (3) PLC and PLD stimulate 
AVP-activated signal transduction in an independent maimer. 
The role of PKC in AVP-induced insulin secretion was investigated in 
RINmSF cells. Ro 31-8220, a specific PKC inhibitor, dose dependently potentiated 
the AVP-induced increase of insulin secretion and elevation of [Ca^""]!. In Ca^"^ free 
medium Ro 31-8220 had no effect on AVP-induced release of intracellular Ca^^. 
Thus, the potentiation of AVP-induced elevation of [Ca'"^]) by Ro 31-8220 was 
mediated by an increase in Ca^^ influx through Ca^"^ channels. However, Ro 31-
8220 did not enhance KCl (10 mM)-induced insulin secretion and elevation of 
[Ca^^];. Acute treatment with a DAG analog, OAG, inhibited AVP-induced insulin 
dose-dependently, but reduced slightly the AVP-induced elevation of [Ca^'^]|. 
Activation of PKC by OAG had no effect on insulin secretion and [Ca^"]). Also 
OAG did not change KCl (10 mM)-induced insulin secretion or elevation of 
[Ca^""]!. These results suggested that: 1) PKC is a negative regulator of AVP's 
action in beta-cells, 2) PKC inhibits Ca^"" channels to regulate insulin secretion, and 
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3) PKC has no effect on AVP-induced intracellular Ca^^ release from pancreatic 
beta-cells. 
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